financetom
Business
financetom
/
Business
/
Exclusive-Wells Fargo hires Paterson from Citi for activism defense
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Exclusive-Wells Fargo hires Paterson from Citi for activism defense
Jun 26, 2025 2:59 AM

NEW YORK (Reuters) -Wells Fargo has hired a senior banker from Citigroup to lead its activism defense practice, as corporations scramble to build out business units to help clients facing pressure from activist investors.

The bank confirmed to Reuters that it is bringing on Muir Paterson as a managing director and head of shareholder advisory and defense from Citigroup where he was a managing director and global head of shareholder advisory and defense. He will report to Jeff Hogan, Wells' head of global mergers and acquisitions.

The hire dovetails with Wells' goal of building out its investment banking division.

Wells Fargo declined to provide additional comment.

Wells has been looking for a senior banker to head its activism defense practice for months, sources contacted about the role said. The move also comes just weeks after Jefferies hired veteran Lazard banker Rich Thomas as its new global head of activism defense and JPMorgan Chase in April hired two veteran bankers, Duncan Herrington and Lyndon Park, in its global shareholder engagement and M&A capital markets group.

Paterson will join Wells after a period of garden leave and work in New York. Before joining Citi in 2017, Paterson worked for Goldman Sachs, Wellington Management and proxy advisory firm Institutional Shareholder Services.

At Citi he helped advise Mercury Systems when Jana Partners and Starboard Value pushed for changes and Berry Global Group in its engagement with Ancora Holdings.

Wells has been busy in building out its M&A business and recently hired two senior bankers from Goldman Sachs, Chris DiOrio and Kieran Ryan, to head industrials M&A and head sponsors M&A respectively.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved